Jason Y. Wang

Jason Y. Wang

Auto-generated profile, based on publicly available information

Jason Y. Wang

Merck & Co., Inc

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2024 in Nature
Verified
Journal Article
Closed access
PDF file
JWJason Y. Wang
Jason Y. Wang
JSJason M. Stevens
Jason M. Stevens
SKStavros K. Kariofillis
Stavros K. Kariofillis
MTMai-Jan Tom
Mai-Jan Tom
DGDung L. Golden
Dung L. Golden
ADAbigail G. Doyle
Abigail G. Doyle

17 October 2022 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
SNSamuel H. Newman-Stonebraker
Samuel H. Newman-Stonebraker
JWJason Y. Wang
Jason Y. Wang
PJPhilip D. Jeffrey
Philip D. Jeffrey
ADAbigail G. Doyle
Abigail G. Doyle

7 December 2018 in ACS Catalysis
Verified
Journal Article
Closed access
BRBenjamin D. Ravetz
Benjamin D. Ravetz
JWJason Y. Wang
Jason Y. Wang
KRKyle E. Ruhl
Kyle E. Ruhl
TRTomislav Rovis
Tomislav Rovis

17 March 2022 in Reaction Chemistry & Engineering
Verified
Journal Article
Closed access
PDF file
AŻAndrzej M. Żurański
Andrzej M. Żurański
JWJason Y. Wang
Jason Y. Wang
BSBenjamin J. Shields
Benjamin J. Shields
ADAbigail G. Doyle
Abigail G. Doyle
This perspective describes Auto-QChem, an automatic, high-throughput and end-to-end DFT calculation workflow that computes chemical descriptors for organic molecules.

13 March 2024 in ACS Catalysis
Verified
Journal Article
Closed access
NRNatalie P. Romer
Natalie P. Romer
DMDaniel S. Min
Daniel S. Min
JWJason Y. Wang
Jason Y. Wang
RWRichard C. Walroth
Richard C. Walroth
KMKyle A. Mack
Kyle A. Mack
MSMatthew S. Sigman
Matthew S. Sigman

2 October 2026 in ChemRxiv
Verified
Preprint
Open access
PDF file
MCMaria A. Castellanos
Maria A. Castellanos
HMHugo MacDermott-Opeskin
Hugo MacDermott-Opeskin
JAJon Ainsley
Jon Ainsley
JSJonathan A. Swain
Jonathan A. Swain
SCSean Colby
Sean Colby
WWW. Patrick Walters
W. Patrick Walters
Computational blind challenges are essential for advancing drug discovery, especially in research areas with limited public data, such as absorption, distribution, metabolism, excretion, toxicity (ADMET) prediction. In this paper, we present the results of our latest community blind challenge, organized in collaboration with Expansion Therapeutics (ExpansionRx). Participants were tasked with predicting nine distinct ADMET endpoints routinely evaluated during lead optimization of compounds in drug discovery programs. Following unprecedented engagement from the global community, this challenge provided valuable insights into the state of the art in machine learning for ADMET modeling. Evaluating submissions against a realistic, challenging dataset from active ExpansionRx drug discovery programs revealed that message-passing neural networks and chemical foundation models dominated among the top performers. Furthermore, the results highlighted the power of proprietary industry datasets and a critical need to optimize predictive workflows for different endpoints independently via multitasking and task-affinity grouping. We also demonstrate how hosting our open-source blind challenge infrastructure on a flexible platform like Hugging Face was pivotal for driving community engagement and visibility. Ultimately, blind challenges supported by robust infrastructure, widespread dissemination, and rigorous post-challenge analysis are fundamental to maximizing the utility of public data releases. We anticipate that these community benchmarks will continue to drive the advancement of ADMET models, enabling their deployment in both early- and late-stage drug discovery.